TY - JOUR AU - Balamuth, N. J. AU - Womer, R. B. PY - 2010 DA - 2010// TI - Ewing’s sarcoma JO - Lancet Oncol VL - 11 UR - https://doi.org/10.1016/S1470-2045(09)70286-4 DO - 10.1016/S1470-2045(09)70286-4 ID - Balamuth2010 ER - TY - JOUR AU - Grünewald, T. G. P. AU - Cidre-Aranaz, F. AU - Surdez, D. AU - Tomazou, E. M. AU - Álava, E. AU - Kovar, H. PY - 2018 DA - 2018// TI - Ewing sarcoma JO - Nat Rev Dis Primers VL - 4 UR - https://doi.org/10.1038/s41572-018-0003-x DO - 10.1038/s41572-018-0003-x ID - Grünewald2018 ER - TY - JOUR AU - Delattre, O. AU - Zucman, J. AU - Plougastel, B. AU - Desmaze, C. AU - Melot, T. AU - Peter, M. PY - 1992 DA - 1992// TI - Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours JO - Nature. VL - 359 UR - https://doi.org/10.1038/359162a0 DO - 10.1038/359162a0 ID - Delattre1992 ER - TY - JOUR AU - Gaspar, N. AU - Hawkins, D. S. AU - Dirksen, U. AU - Lewis, I. J. AU - Ferrari, S. AU - Deley, M. -. C. PY - 2015 DA - 2015// TI - Ewing sarcoma: current management and future approaches through collaboration JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.59.5256 DO - 10.1200/JCO.2014.59.5256 ID - Gaspar2015 ER - TY - JOUR AU - Womer, R. B. AU - West, D. C. AU - Krailo, M. D. AU - Dickman, P. S. AU - Pawel, B. R. AU - Grier, H. E. PY - 2012 DA - 2012// TI - Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children’s oncology group JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.41.5703 DO - 10.1200/JCO.2011.41.5703 ID - Womer2012 ER - TY - JOUR AU - Marina, N. M. AU - Liu, Q. AU - Donaldson, S. S. AU - Sklar, C. A. AU - Armstrong, G. T. AU - Oeffinger, K. C. PY - 2017 DA - 2017// TI - Longitudinal follow-up of adult survivors of Ewing sarcoma: a report from the childhood Cancer survivor study JO - Cancer. VL - 123 UR - https://doi.org/10.1002/cncr.30627 DO - 10.1002/cncr.30627 ID - Marina2017 ER - TY - JOUR AU - Goss, K. L. AU - Gordon, D. J. PY - 2016 DA - 2016// TI - Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma JO - Oncotarget VL - 7 UR - https://doi.org/10.18632/oncotarget.11416 DO - 10.18632/oncotarget.11416 ID - Goss2016 ER - TY - JOUR AU - Corsello, S. M. AU - Nagari, R. T. AU - Spangler, R. D. AU - Rossen, J. AU - Kocak, M. AU - Bryan, J. G. PY - 2020 DA - 2020// TI - Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling JO - Nat Cancer VL - 1 UR - https://doi.org/10.1038/s43018-019-0018-6 DO - 10.1038/s43018-019-0018-6 ID - Corsello2020 ER - TY - JOUR AU - Jenkins, J. M. AU - Williams, D. AU - Deng, Y. AU - Uhl, J. AU - Kitchen, V. AU - Collins, D. PY - 2007 DA - 2007// TI - Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist JO - Blood. VL - 109 UR - https://doi.org/10.1182/blood-2006-11-057968 DO - 10.1182/blood-2006-11-057968 ID - Jenkins2007 ER - TY - JOUR AU - Winer, E. S. AU - Safran, H. AU - Karaszewska, B. AU - Richards, D. A. AU - Hartner, L. AU - Forget, F. PY - 2015 DA - 2015// TI - Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study JO - Cancer Med VL - 4 UR - https://doi.org/10.1002/cam4.326 DO - 10.1002/cam4.326 ID - Winer2015 ER - TY - JOUR AU - Zhang, X. AU - Chuai, Y. AU - Nie, W. AU - Wang, A. AU - Dai, G. PY - 2017 DA - 2017// TI - Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours JO - Cochrane Database Syst Rev VL - 11 UR - https://doi.org/10.1002/14651858.CD012035.pub2 DO - 10.1002/14651858.CD012035.pub2 ID - Zhang2017 ER - TY - JOUR AU - Kurokawa, T. AU - Murata, S. AU - Zheng, Y. -. W. AU - Iwasaki, K. AU - Kohno, K. AU - Fukunaga, K. PY - 2015 DA - 2015// TI - The Eltrombopag antitumor effect on hepatocellular carcinoma JO - Int J Oncol VL - 47 UR - https://doi.org/10.3892/ijo.2015.3180 DO - 10.3892/ijo.2015.3180 ID - Kurokawa2015 ER - TY - JOUR AU - Roth, M. AU - Will, B. AU - Simkin, G. AU - Narayanagari, S. AU - Barreyro, L. AU - Bartholdy, B. PY - 2012 DA - 2012// TI - Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation JO - Blood. VL - 120 UR - https://doi.org/10.1182/blood-2011-12-399667 DO - 10.1182/blood-2011-12-399667 ID - Roth2012 ER - TY - JOUR AU - Vlachodimitropoulou, E. AU - Chen, Y. -. L. AU - Garbowski, M. AU - Koonyosying, P. AU - Psaila, B. AU - Sola-Visner, M. PY - 2017 DA - 2017// TI - Eltrombopag: a powerful chelator of cellular or extracellular iron (III) alone or combined with a second chelator JO - Blood. VL - 130 UR - https://doi.org/10.1182/blood-2016-10-740241 DO - 10.1182/blood-2016-10-740241 ID - Vlachodimitropoulou2017 ER - TY - STD TI - DepMap: The Cancer Dependency Map Project at Broad Institute. https://depmap.org/portal/. Accessed 8 Jan 2020. UR - https://depmap.org/portal/ ID - ref15 ER - TY - STD TI - cBioPortal for Cancer Genomics. https://www.cbioportal.org/. Accessed 12 Apr 2020. UR - https://www.cbioportal.org/ ID - ref16 ER - TY - JOUR AU - Koppenhafer, S. L. AU - Goss, K. L. AU - Terry, W. W. AU - Gordon, D. J. PY - 2020 DA - 2020// TI - Inhibition of the ATR-CHK1 pathway in Ewing sarcoma cells causes DNA damage and apoptosis via the CDK2-mediated degradation of RRM2 JO - Mol Cancer Res VL - 18 UR - https://doi.org/10.1158/1541-7786.MCR-19-0585 DO - 10.1158/1541-7786.MCR-19-0585 ID - Koppenhafer2020 ER - TY - JOUR AU - Huang, X. AU - Darzynkiewicz, Z. PY - 2006 DA - 2006// TI - Cytometric assessment of histone H2AX phosphorylation: a reporter of DNA damage JO - Methods Mol Biol VL - 314 UR - https://doi.org/10.1385/1-59259-973-7:073 DO - 10.1385/1-59259-973-7:073 ID - Huang2006 ER - TY - JOUR AU - Koppenhafer, S. L. AU - Goss, K. L. AU - Terry, W. W. AU - Gordon, D. J. PY - 2018 DA - 2018// TI - mTORC1/2 and protein translation regulate levels of CHK1 and the sensitivity to CHK1 inhibitors in Ewing sarcoma cells JO - Mol Cancer Ther VL - 17 UR - https://doi.org/10.1158/1535-7163.MCT-18-0260 DO - 10.1158/1535-7163.MCT-18-0260 ID - Koppenhafer2018 ER - TY - JOUR AU - Goss, K. L. AU - Koppenhafer, S. L. AU - Harmoney, K. M. AU - Terry, W. W. AU - Gordon, D. J. PY - 2017 DA - 2017// TI - Inhibition of CHK1 sensitizes Ewing sarcoma cells to the ribonucleotide reductase inhibitor gemcitabine JO - Oncotarget VL - 8 UR - https://doi.org/10.18632/oncotarget.18776 DO - 10.18632/oncotarget.18776 ID - Goss2017 ER - TY - JOUR AU - Grant, G. D. AU - Kedziora, K. M. AU - Limas, J. C. AU - Cook, J. G. AU - Purvis, J. E. PY - 2018 DA - 2018// TI - Accurate delineation of cell cycle phase transitions in living cells with PIP-FUCCI JO - Cell Cycle VL - 17 UR - https://doi.org/10.1080/15384101.2018.1547001 DO - 10.1080/15384101.2018.1547001 ID - Grant2018 ER - TY - JOUR AU - Garnett, M. J. AU - Edelman, E. J. AU - Heidorn, S. J. AU - Greenman, C. D. AU - Dastur, A. AU - Lau, K. W. PY - 2012 DA - 2012// TI - Systematic identification of genomic markers of drug sensitivity in cancer cells JO - Nature. VL - 483 UR - https://doi.org/10.1038/nature11005 DO - 10.1038/nature11005 ID - Garnett2012 ER - TY - JOUR AU - Gill, S. J. AU - Travers, J. AU - Pshenichnaya, I. AU - Kogera, F. A. AU - Barthorpe, S. AU - Mironenko, T. PY - 2015 DA - 2015// TI - Combinations of PARP inhibitors with Temozolomide drive PARP1 trapping and apoptosis in Ewing’s sarcoma JO - PLoS One VL - 10 UR - https://doi.org/10.1371/journal.pone.0140988 DO - 10.1371/journal.pone.0140988 ID - Gill2015 ER - TY - JOUR AU - Lee, H. -. J. AU - Yoon, C. AU - Schmidt, B. AU - Park, D. J. AU - Zhang, A. Y. AU - Erkizan, H. V. PY - 2013 DA - 2013// TI - Combining PARP-1 inhibition and radiation in Ewing sarcoma results in lethal DNA damage JO - Mol Cancer Ther VL - 12 UR - https://doi.org/10.1158/1535-7163.MCT-13-0338 DO - 10.1158/1535-7163.MCT-13-0338 ID - Lee2013 ER - TY - JOUR AU - Engert, F. AU - Schneider, C. AU - Weiβ, L. M. AU - Probst, M. AU - Fulda, S. PY - 2015 DA - 2015// TI - PARP inhibitors sensitize Ewing sarcoma cells to Temozolomide-induced apoptosis via the mitochondrial pathway JO - Mol Cancer Ther VL - 14 UR - https://doi.org/10.1158/1535-7163.MCT-15-0587 DO - 10.1158/1535-7163.MCT-15-0587 ID - Engert2015 ER - TY - JOUR AU - Brenner, J. C. AU - Feng, F. Y. AU - Han, S. AU - Patel, S. AU - Goyal, S. V. AU - Bou-Maroun, L. M. PY - 2012 DA - 2012// TI - PARP-1 inhibition as a targeted strategy to treat Ewing’s sarcoma JO - Cancer Res VL - 72 UR - https://doi.org/10.1158/0008-5472.CAN-11-3648 DO - 10.1158/0008-5472.CAN-11-3648 ID - Brenner2012 ER - TY - JOUR AU - Ordóñez, J. L. AU - Amaral, A. T. AU - Carcaboso, A. M. AU - Herrero-Martín, D. AU - Carmen García-Macías, M. AU - Sevillano, V. PY - 2015 DA - 2015// TI - The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin JO - Oncotarget VL - 6 UR - https://doi.org/10.18632/oncotarget.4303 DO - 10.18632/oncotarget.4303 ID - Ordóñez2015 ER - TY - JOUR AU - Vormoor, B. AU - Curtin, N. J. PY - 2014 DA - 2014// TI - Poly (ADP-ribose) polymerase inhibitors in Ewing sarcoma JO - Curr Opin Oncol VL - 26 UR - https://doi.org/10.1097/CCO.0000000000000091 DO - 10.1097/CCO.0000000000000091 ID - Vormoor2014 ER - TY - JOUR AU - Smith, M. A. AU - Reynolds, C. P. AU - Kang, M. H. AU - Kolb, E. A. AU - Gorlick, R. AU - Carol, H. PY - 2015 DA - 2015// TI - Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program JO - Clin Cancer Res VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-14-2572 DO - 10.1158/1078-0432.CCR-14-2572 ID - Smith2015 ER - TY - JOUR AU - Choy, E. AU - Butrynski, J. E. AU - Harmon, D. C. AU - Morgan, J. A. AU - George, S. AU - Wagner, A. J. PY - 2014 DA - 2014// TI - Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy JO - BMC Cancer VL - 14 UR - https://doi.org/10.1186/1471-2407-14-813 DO - 10.1186/1471-2407-14-813 ID - Choy2014 ER - TY - JOUR AU - Debili, N. AU - Wendling, F. AU - Cosman, D. AU - Titeux, M. AU - Florindo, C. AU - Dusanter-Fourt, I. PY - 1995 DA - 1995// TI - The Mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets JO - Blood. VL - 85 UR - https://doi.org/10.1182/blood.V85.2.391.391 DO - 10.1182/blood.V85.2.391.391 ID - Debili1995 ER - TY - JOUR AU - Zhan, J. AU - Felder, B. AU - Ellison, A. R. AU - Winters, A. AU - Salimi-Moosavi, H. AU - Scully, S. PY - 2013 DA - 2013// TI - Novel anti-c-Mpl monoclonal antibodies identified multiple differentially glycosylated human c-Mpl proteins in megakaryocytic cells but not in human solid tumors JO - Monoclon Antib Immunodiagn Immunother VL - 32 UR - https://doi.org/10.1089/mab.2012.0117 DO - 10.1089/mab.2012.0117 ID - Zhan2013 ER - TY - JOUR AU - Drexler, H. G. AU - Quentmeier, H. PY - 1996 DA - 1996// TI - Thrombopoietin: expression of its receptor MPL and proliferative effects on leukemic cells JO - Leukemia. VL - 10 ID - Drexler1996 ER - TY - JOUR AU - Williams, D. D. AU - Peng, B. AU - Bailey, C. K. AU - Wire, M. B. AU - Deng, Y. AU - Park, J. W. PY - 2009 DA - 2009// TI - Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies JO - Clin Ther VL - 31 UR - https://doi.org/10.1016/j.clinthera.2009.04.010 DO - 10.1016/j.clinthera.2009.04.010 ID - Williams2009 ER - TY - JOUR AU - Deng, Y. AU - Madatian, A. AU - Wire, M. B. AU - Bowen, C. AU - Park, J. W. AU - Williams, D. PY - 2011 DA - 2011// TI - Metabolism and disposition of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist, in healthy human subjects JO - Drug Metab Dispos VL - 39 UR - https://doi.org/10.1124/dmd.111.040170 DO - 10.1124/dmd.111.040170 ID - Deng2011 ER - TY - JOUR AU - Greene, B. L. AU - Kang, G. AU - Cui, C. AU - Bennati, M. AU - Nocera, D. G. AU - Drennan, C. L. PY - 2020 DA - 2020// TI - Ribonucleotide reductases: structure, chemistry, and metabolism suggest new therapeutic targets JO - Annu Rev Biochem VL - 89 UR - https://doi.org/10.1146/annurev-biochem-013118-111843 DO - 10.1146/annurev-biochem-013118-111843 ID - Greene2020 ER - TY - JOUR AU - Feijoo, C. AU - Hall-Jackson, C. AU - Wu, R. AU - Jenkins, D. AU - Leitch, J. AU - Gilbert, D. M. PY - 2001 DA - 2001// TI - Activation of mammalian Chk1 during DNA replication arrest: a role for Chk1 in the intra-S phase checkpoint monitoring replication origin firing JO - J Cell Biol VL - 154 UR - https://doi.org/10.1083/jcb.200104099 DO - 10.1083/jcb.200104099 ID - Feijoo2001 ER - TY - JOUR AU - Bartek, J. AU - Lukas, J. PY - 2003 DA - 2003// TI - Chk1 and Chk2 kinases in checkpoint control and cancer JO - Cancer Cell VL - 3 UR - https://doi.org/10.1016/s1535-6108(03)00110-7 DO - 10.1016/s1535-6108(03)00110-7 ID - Bartek2003 ER - TY - JOUR AU - Cho, S. H. AU - Toouli, C. D. AU - Fujii, G. H. AU - Crain, C. AU - Parry, D. PY - 2005 DA - 2005// TI - Chk1 is essential for tumor cell viability following activation of the replication checkpoint JO - Cell Cycle VL - 4 UR - https://doi.org/10.4161/cc.4.1.1299 DO - 10.4161/cc.4.1.1299 ID - Cho2005 ER - TY - JOUR AU - Ewald, B. AU - Sampath, D. AU - Plunkett, W. PY - 2007 DA - 2007// TI - H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation JO - Mol Cancer Ther VL - 6 UR - https://doi.org/10.1158/1535-7163.MCT-06-0633 DO - 10.1158/1535-7163.MCT-06-0633 ID - Ewald2007 ER - TY - JOUR AU - Gagou, M. E. AU - Zuazua-Villar, P. AU - Meuth, M. PY - 2010 DA - 2010// TI - Enhanced H2AX phosphorylation, DNA replication fork arrest, and cell death in the absence of Chk1 JO - Mol Biol Cell VL - 21 UR - https://doi.org/10.1091/mbc.E09-07-0618 DO - 10.1091/mbc.E09-07-0618 ID - Gagou2010 ER - TY - JOUR AU - Firsanov, D. V. AU - Solovjeva, L. V. AU - Svetlova, M. P. PY - 2011 DA - 2011// TI - H2AX phosphorylation at the sites of DNA double-strand breaks in cultivated mammalian cells and tissues JO - Clin Epigenetics VL - 2 UR - https://doi.org/10.1007/s13148-011-0044-4 DO - 10.1007/s13148-011-0044-4 ID - Firsanov2011 ER - TY - JOUR AU - Tang, S. -. W. AU - Bilke, S. AU - Cao, L. AU - Murai, J. AU - Sousa, F. G. AU - Yamade, M. PY - 2015 DA - 2015// TI - SLFN11 is a transcriptional target of EWS-FLI1 and a determinant of drug response in Ewing sarcoma JO - Clin Cancer Res VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-14-2112 DO - 10.1158/1078-0432.CCR-14-2112 ID - Tang2015 ER - TY - STD TI - Murai J, Thomas A, Miettinen M, Pommier Y. Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies. Pharmacol Ther. 2019. https://doi.org/10.1016/j.pharmthera.2019.05.009. ID - ref44 ER - TY - JOUR AU - Murai, J. AU - Tang, S. -. W. AU - Leo, E. AU - Baechler, S. A. AU - Redon, C. E. AU - Zhang, H. PY - 2018 DA - 2018// TI - SLFN11 blocks stressed replication forks independently of ATR JO - Mol Cell VL - 69 UR - https://doi.org/10.1016/j.molcel.2018.01.012 DO - 10.1016/j.molcel.2018.01.012 ID - Murai2018 ER - TY - JOUR AU - Zoppoli, G. AU - Regairaz, M. AU - Leo, E. AU - Reinhold, W. C. AU - Varma, S. AU - Ballestrero, A. PY - 2012 DA - 2012// TI - Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents JO - Proc Natl Acad Sci U S A VL - 109 UR - https://doi.org/10.1073/pnas.1205943109 DO - 10.1073/pnas.1205943109 ID - Zoppoli2012 ER - TY - JOUR AU - Mu, Y. AU - Lou, J. AU - Srivastava, M. AU - Zhao, B. AU - Feng, X. AU - Liu, T. PY - 2016 DA - 2016// TI - SLFN11 inhibits checkpoint maintenance and homologous recombination repair JO - EMBO Rep VL - 17 UR - https://doi.org/10.15252/embr.201540964 DO - 10.15252/embr.201540964 ID - Mu2016 ER - TY - JOUR AU - Reinhold, W. C. AU - Varma, S. AU - Sunshine, M. AU - Rajapakse, V. AU - Luna, A. AU - Kohn, K. W. PY - 2017 DA - 2017// TI - The NCI-60 Methylome and Its Integration into CellMiner JO - Cancer Res VL - 77 UR - https://doi.org/10.1158/0008-5472.CAN-16-0655 DO - 10.1158/0008-5472.CAN-16-0655 ID - Reinhold2017 ER - TY - JOUR AU - Tang, S. -. W. AU - Thomas, A. AU - Murai, J. AU - Trepel, J. B. AU - Bates, S. E. AU - Rajapakse, V. N. PY - 2018 DA - 2018// TI - Overcoming resistance to DNA-targeted agents by epigenetic activation of Schlafen 11 (SLFN11) expression with class I histone Deacetylase inhibitors JO - Clin Cancer Res VL - 24 UR - https://doi.org/10.1158/1078-0432.CCR-17-0443 DO - 10.1158/1078-0432.CCR-17-0443 ID - Tang2018 ER - TY - JOUR AU - Pedrosa, F. AU - Coustan-Smith, E. AU - Zhou, Y. AU - Cheng, C. AU - Pedrosa, A. AU - Lins, M. M. PY - 2020 DA - 2020// TI - Reduced-dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study JO - Blood. VL - 135 UR - https://doi.org/10.1182/blood.2019004215 DO - 10.1182/blood.2019004215 ID - Pedrosa2020 ER - TY - JOUR AU - Winer, E. S. AU - Safran, H. AU - Karaszewska, B. AU - Bauer, S. AU - Khan, D. AU - Doerfel, S. PY - 2017 DA - 2017// TI - Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study JO - Int J Hematol VL - 106 UR - https://doi.org/10.1007/s12185-017-2319-9 DO - 10.1007/s12185-017-2319-9 ID - Winer2017 ER - TY - JOUR AU - Ghanima, W. AU - Cooper, N. AU - Rodeghiero, F. AU - Godeau, B. AU - Bussel, J. B. PY - 2019 DA - 2019// TI - Thrombopoietin receptor agonists: ten years later JO - Haematologica. VL - 104 UR - https://doi.org/10.3324/haematol.2018.212845 DO - 10.3324/haematol.2018.212845 ID - Ghanima2019 ER - TY - JOUR AU - Bussel, J. B. AU - Miguel, P. G. AU - Despotovic, J. M. AU - Grainger, J. D. AU - Sevilla, J. AU - Blanchette, V. S. PY - 2015 DA - 2015// TI - Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study JO - Lancet Haematol VL - 2 UR - https://doi.org/10.1016/S2352-3026(15)00114-3 DO - 10.1016/S2352-3026(15)00114-3 ID - Bussel2015 ER - TY - JOUR AU - Wong, R. S. M. AU - Saleh, M. N. AU - Khelif, A. AU - Salama, A. AU - Portella, M. S. O. AU - Burgess, P. PY - 2017 DA - 2017// TI - Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study JO - Blood. VL - 130 UR - https://doi.org/10.1182/blood-2017-04-748707 DO - 10.1182/blood-2017-04-748707 ID - Wong2017 ER - TY - JOUR AU - Shi, M. AU - Xu, F. AU - Yang, X. AU - Bai, Y. AU - Niu, J. AU - Drokow, E. K. PY - 2019 DA - 2019// TI - The synergistic antileukemic effects of eltrombopag and decitabine in myeloid leukemia cells JO - Cancer Manag Res VL - 11 UR - https://doi.org/10.2147/CMAR.S213931 DO - 10.2147/CMAR.S213931 ID - Shi2019 ER - TY - JOUR AU - Whelan, J. AU - Khan, A. AU - Sharma, A. AU - Rothermundt, C. AU - Dileo, P. AU - Michelagnoli, M. PY - 2012 DA - 2012// TI - Interval compressed vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide, etoposide in patients with advanced Ewing’s and other small round cell sarcomas JO - Clin Sarcoma Res VL - 2 UR - https://doi.org/10.1186/2045-3329-2-12 DO - 10.1186/2045-3329-2-12 ID - Whelan2012 ER - TY - JOUR AU - Shee, K. AU - Wells, J. D. AU - Jiang, A. AU - Miller, T. W. PY - 2019 DA - 2019// TI - Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy JO - PLoS One VL - 14 UR - https://doi.org/10.1371/journal.pone.0224267 DO - 10.1371/journal.pone.0224267 ID - Shee2019 ER - TY - JOUR AU - Nogales, V. AU - Reinhold, W. C. AU - Varma, S. AU - Martinez-Cardus, A. AU - Moutinho, C. AU - Moran, S. PY - 2016 DA - 2016// TI - Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs JO - Oncotarget VL - 7 UR - https://doi.org/10.18632/oncotarget.6413 DO - 10.18632/oncotarget.6413 ID - Nogales2016 ER -